ClinCalc Pro
Menu
KRAS G12C inhibitor

Sotorasib (Specialist drug)

Brand names: Lumykras

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD

Clinical pearls

  • KRAS G12C-mutated metastatic NSCLC after prior systemic therapy
  • Specialist oncology

Contraindications

  • Hypersensitivity
  • Severe hepatic impairment

Side effects

  • Hepatotoxicity
  • ILD/pneumonitis
  • Diarrhoea
  • Nausea
  • Fatigue
  • QT prolongation

Interactions

  • Acid-reducing agents (avoid PPIs/H2)
  • Strong CYP3A4 inducers

Monitoring

  • LFTs
  • Pulmonary symptoms

Reference: BNF; NICE TA781; SmPC; https://bnf.nice.org.uk/drugs/sotorasib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.